The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.